• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

遗传性乳腺癌中基于DNA的BRCA1/BRCA2基因咨询的最新进展。

An update on DNA-based BRCA1/BRCA2 genetic counseling in hereditary breast cancer.

作者信息

Lynch H T, Watson P, Tinley S, Snyder C, Durham C, Lynch J, Kirnarsky Y, Serova O, Lenoir G, Lerman C, Narod S A

机构信息

Department of Preventive Medicine and Public Health, Creighton University School of Medicine, Omaha, Nebraska 68178, USA.

出版信息

Cancer Genet Cytogenet. 1999 Mar;109(2):91-8. doi: 10.1016/s0165-4608(98)00165-4.

DOI:10.1016/s0165-4608(98)00165-4
PMID:10087939
Abstract

The identification of BRCA1 and BRCA2 mutations has enabled physicians to identify persons at high risk for carcinoma of the breast and ovary in hereditary breast-ovarian cancer (HBOC) families. Many physicians have limited knowledge about the effective translation of these new discoveries into clinical practice settings. This problem is further confounded by the limited number of genetic counselors who have experience with cancer genetics. Genetic counseling about DNA test results was provided to 420 patients from 37 HBC/HBOC families. Descriptive data were collected and recorded about their responses to questions posed immediately before and after test results were disclosed. Findings disclosed a significant tendency of patients to overestimate rather than underestimate their risk (P < .001) prior to receiving results. The chief reason for declining to receive results was fear of insurance discrimination. The primary reason that patients sought test results was for their children. Most women reported that, if testing identified them as mutation carriers, they would consider lifetime surveillance and prophylactic surgery. Responses to DNA test results were varied and often unpredictable. Counseling by an appropriately educated and skilled professional is essential to assist people in making decisions regarding testing and health management.

摘要

BRCA1和BRCA2基因突变的鉴定使医生能够识别遗传性乳腺癌-卵巢癌(HBOC)家族中患乳腺癌和卵巢癌风险较高的人群。许多医生对将这些新发现有效转化为临床实践的了解有限。经验丰富的癌症遗传学遗传咨询师数量有限,这一问题更加复杂。为来自37个HBC/HBOC家族的420名患者提供了关于DNA检测结果的遗传咨询。收集并记录了他们对在检测结果披露前后立即提出的问题的回答的描述性数据。研究结果显示,在收到结果之前,患者有显著高估而非低估自身风险的倾向(P <.001)。拒绝接受结果的主要原因是担心保险歧视。患者寻求检测结果的主要原因是为了他们的孩子。大多数女性报告称,如果检测确定她们为突变携带者,她们会考虑进行终身监测和预防性手术。对DNA检测结果的反应各不相同,而且往往不可预测。由受过适当教育和训练有素的专业人员进行咨询对于帮助人们就检测和健康管理做出决策至关重要。

相似文献

1
An update on DNA-based BRCA1/BRCA2 genetic counseling in hereditary breast cancer.遗传性乳腺癌中基于DNA的BRCA1/BRCA2基因咨询的最新进展。
Cancer Genet Cytogenet. 1999 Mar;109(2):91-8. doi: 10.1016/s0165-4608(98)00165-4.
2
BRCA1 testing in families with hereditary breast-ovarian cancer. A prospective study of patient decision making and outcomes.遗传性乳腺癌-卵巢癌家族中的BRCA1检测。一项关于患者决策及结果的前瞻性研究。
JAMA. 1996 Jun 26;275(24):1885-92.
3
Histology of prophylactically removed ovaries from BRCA1 and BRCA2 mutation carriers compared with noncarriers in hereditary breast ovarian cancer syndrome kindreds.与遗传性乳腺癌卵巢癌综合征家系中的非携带者相比,BRCA1和BRCA2突变携带者预防性切除卵巢的组织学情况。
Gynecol Oncol. 2000 Sep;78(3 Pt 1):278-87. doi: 10.1006/gyno.2000.5861.
4
Presymptomatic DNA testing and prophylactic surgery in families with a BRCA1 or BRCA2 mutation.有BRCA1或BRCA2基因突变家族中的症状前DNA检测和预防性手术。
Lancet. 2000 Jun 10;355(9220):2015-20. doi: 10.1016/s0140-6736(00)02347-3.
5
Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations.与BRCA1和BRCA2基因突变相关的遗传性乳腺癌卵巢癌综合征家族中女性接受预防性卵巢切除术后的腹腔内癌转移
Gynecol Oncol. 2005 May;97(2):457-67. doi: 10.1016/j.ygyno.2005.01.039.
6
Prevalence of BRCA1/BRCA2 mutations in a Brazilian population sample at-risk for hereditary breast cancer and characterization of its genetic ancestry.巴西遗传性乳腺癌高危人群样本中BRCA1/BRCA2突变的患病率及其遗传谱系特征
Oncotarget. 2016 Dec 6;7(49):80465-80481. doi: 10.18632/oncotarget.12610.
7
Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.斯洛伐克遗传性乳腺癌/卵巢癌家系的综合遗传特征分析。
Breast Cancer Res Treat. 2011 Feb;126(1):119-30. doi: 10.1007/s10549-010-1325-x. Epub 2011 Jan 4.
8
Risk estimation as a decision-making tool for genetic analysis of the breast cancer susceptibility genes. EC Demonstration Project on Familial Breast Cancer.风险评估作为乳腺癌易感基因遗传分析的决策工具。欧洲委员会家族性乳腺癌示范项目。
Dis Markers. 1999 Oct;15(1-3):53-65. doi: 10.1155/1999/238375.
9
Factors associated with decisions about clinical BRCA1/2 testing.与临床BRCA1/2检测决策相关的因素。
Cancer Epidemiol Biomarkers Prev. 2000 Nov;9(11):1251-4.
10
Prevention and therapy for BRCA1/2 mutation carriers and women at high risk for breast and ovarian cancer.BRCA1/2 基因突变携带者以及乳腺癌和卵巢癌高危女性的预防与治疗。
Eur J Cancer Prev. 2000 Jun;9(3):139-50.

引用本文的文献

1
The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer.BRCA2突变状态作为胰腺癌诊断、预测和预后生物标志物的作用。
Biomed Res Int. 2016;2016:1869304. doi: 10.1155/2016/1869304. Epub 2016 Dec 18.
2
Global trends on fears and concerns of genetic discrimination: a systematic literature review.全球对遗传歧视的恐惧和担忧趋势:系统文献综述。
J Hum Genet. 2016 Apr;61(4):275-82. doi: 10.1038/jhg.2015.151. Epub 2016 Jan 7.
3
Writing Effective Insurance Justification Letters for Cancer Genetic Testing: A Streamlined Approach.
撰写有效的癌症基因检测保险理赔信:一种简化方法。
J Genet Couns. 2001 Aug;10(4):331-41. doi: 10.1023/A:1016629227338.
4
Acceptance of genetic counseling and testing in a hospital-based series of patients with gynecological cancer.在一系列以医院为基础的妇科癌症患者中对遗传咨询和检测的接受情况。
J Genet Couns. 2013 Jun;22(3):345-57. doi: 10.1007/s10897-012-9553-3. Epub 2012 Nov 30.
5
Haplotype analysis of the 185delAG BRCA1 mutation in ethnically diverse populations.对不同种族人群中 BRCA1 基因 185delAG 突变的单体型分析。
Eur J Hum Genet. 2013 Feb;21(2):212-6. doi: 10.1038/ejhg.2012.124. Epub 2012 Jul 4.
6
Withdrawal from genetic counselling for cancer.停止癌症遗传咨询服务。
Hered Cancer Clin Pract. 2005 Feb 15;3(1):19-27. doi: 10.1186/1897-4287-3-1-19.
7
Survey of unaffected BRCA and mismatch repair (MMR) mutation positive individuals.未受影响的 BRCA 和错配修复(MMR)突变阳性个体的调查。
Fam Cancer. 2009;8(4):363-9. doi: 10.1007/s10689-009-9248-6. Epub 2009 May 24.
8
Results of an intervention for individuals and families with BRCA mutations: a model for providing medical updates and psychosocial support following genetic testing.针对携带BRCA突变的个人和家庭的干预结果:一种在基因检测后提供医学进展信息和心理社会支持的模式。
J Genet Couns. 2007 Aug;16(4):433-56. doi: 10.1007/s10897-006-9078-8. Epub 2007 Jun 27.
9
A cancer-associated PCNA expressed in breast cancer has implications as a potential biomarker.在乳腺癌中表达的一种癌症相关增殖细胞核抗原具有作为潜在生物标志物的意义。
Proc Natl Acad Sci U S A. 2006 Dec 19;103(51):19472-7. doi: 10.1073/pnas.0604614103. Epub 2006 Dec 11.
10
Evaluation of models to predict BRCA germline mutations.预测BRCA种系突变的模型评估。
Br J Cancer. 2006 Oct 9;95(7):914-20. doi: 10.1038/sj.bjc.6603358.